The Analysis Of70Clinical Cases Of Liver Cancer With Radiofrequency Ablation Therapy With Real-time Contrast-enhanced Ultrasonography

Objective：The aim of this study was to investigate the value of clinical application ofreal-time contrast-enhanced ultrasonography in radiofrequency ablation fortreatment of primary liver cancer.Methods：From September,2012to June,2013,70patients with primary liver cancerreceived real-time contrast-enhanced ultrasonography (CEUS) examinationbefore radiofrequency ablation (RFA), and other74patients from May,2011toAugust,2012that only received B-mode ultrasound (US) before RFA wereserved as a control group in the Cancer Center of the First Hospital of JilinUniversity. The clinical characteristics (gender, age, Child classification, tumorsize, quantity, etc.), preoperative coincidence rate of CT/MRI examination,postoperative complications (such as fever, pain, high blood pressure, bleedingetc.) were compared between two group. Also the efficacy evaluated byenhanced CT or (and) MRI1month later after surgery, then following-up byenhanced CT or (and) MRI every three months, the progression-free survivalwere in comparison either. Results:In the CEUS group，70patients had100lesions，56cases (80%)showedenhancement on arterial phase，while53cases (75%) were arterial demonstratedby enhanced CT/MRI. Forty nine cases showed the enhancement in both of theCEUS and the enhanced CT/MRI examination. The lesion size (2.72±0.933cm)of tumors defined by CEUS were larger than the lesion size (2.53±0.944cm) ofUS，which had a statistically significant difference between the two comparison(P=0.042). Compared with the ordinary ultrasound which had43casescomplications in patients (58.1%), CEUS group of patients with postoperativecomplications of34cases (48.6%), which had no statistically significant(P>0.05). Followed by CT or (and) MR after1month，6patients relapsed inCEUS group， while18patients had local recurrence (24.3%)， and thecomparison had statistically significant difference (χ2=6.427, P<0.05). Medianfollowing-up time was12months with the patients in two groups (4to16months),6month progression-free survival CEUS group was64.3%, ordinaryultrasound group was46.1%;1-year progression-free survival in CEUS groupwas75.7%, general ultrasound group was54.1%. The median survival ofordinary contrast ultrasound contrast group was11.7months, comparing withthe CEUS group which had not been reached, which mean a statisticallysignificant (P <0.05). For the cases with lesion size lager than3cm，6monthprogression-free survival CEUS group was74.8%, ordinary ultrasound groupwas48.0%;1-year progression-free survival in CEUS group was68.0%,general ultrasound group was30.8%. The median survival of ordinary contrast ultrasound contrast group was6.6months, comparing with the CEUS groupwhich had not been reached, which mean a statistically significant (P <0.05).Conclusion：CEUS can be used as a useful supplement of CT or MRI, it can play aguiding role in real-time in radiofrequency ablation, and reduces local tumorsurvival and prolong disease-free survival, and decreases the occurrence of theassociated complications to some extent.